News: Year - 2012

Press Releases
Kane Biotech Announces Closing of Private Placement Offering

WINNIPEG, Manitoba (December 14, 2012) – Kane Biotech Inc. (TSX-V:KNE) (the “Corporation”) today announced closing of the Corporation’s previously announced non-brokered private placement offering (the “Offering”) units (“Units”) at a price of $0.08 per Unit. Each Unit is comprised of…

> Read More

Press Releases
Kane Biotech Appoints Dr. Arvind K. Joshi, M.D. to the Board of Directors

WINNIPEG, Manitoba (November 28, 2012) – Kane Biotech Inc. (TSX-V: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, announces today the appointment of Dr. Arvind K. Joshi, M.D. F.R.C.S.(C),F.A.C.O.G.,M.B.A.,C.H.E.to its Board of Directors.

Dr.…

> Read More

Press Releases
Kane Biotech Receives Health Canada Approval for KBI Disinfectant Label Expansion

WINNIPEG, Manitoba (November 27, 2012) – Kane Biotech Inc. (TSX-V: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received approval from the Therapeutic Products…

> Read More

Press Releases
Kane Biotech Prepares to Launch StrixNB™ Pet Oral Care Product

WINNIPEG, Manitoba (November 20, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received Notification Number“NN.W33A” from the Low Risk…

> Read More

Press Releases
Kane Biotech Successfully Completes Veterinary Clinic Testing of StrixNB™

WINNIPEG, Manitoba (November 15, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces it has successfully completed the veterinary clinic testing of its pet oral…

> Read More

Press Releases
Kane Biotech Announces Private Placement Offering

WINNIPEG, Manitoba (November 14, 2012) – Kane Biotech Inc. (TSX-V:KNE)(the “Corporation”) today announced the intention of the Corporation to undertake a non-brokered private placement offering (the “Offering”) of up to 18,750,000 units (“Units”) at a price of $0.08 per Unit…

> Read More

Press Releases
Kane Biotech Issued New Patent in Australia for Aledex®

WINNIPEG, Manitoba (November 06, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.2006265707) entitled “Antimicrobial compositions for…

> Read More

Press Releases
Kane Biotech and Avmor Sign Licensing Agreement for KBI Disinfectant in Canada

WINNIPEG, Manitoba (October 25, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has signed a non-exclusive licensing agreement…

> Read More

Press Releases
Kane Biotech Issued New Patent in Japan for DispersinB®

WINNIPEG, MB. (October 16, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.5073169) entitled “Compositions and Methods…

> Read More

Press Releases
Kane Biotech Completes Pilot Manufacturing Phase of StrixNB™ Oral Care Product

WINNIPEG, MB. (October 10, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has successfully developed the manufacturing process…

> Read More